一分钟看懂
这是一项关于小细胞肺癌的III 期研究，登记的药物或干预包括BMS-986489 (Atigotatug+Nivolumab)；Atezolizumab；Carboplatin；Etoposide，当前状态为招募中。登记地点显示中国北京、重庆、福州、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BMS-986489 (Atigotatug+Nivolumab)；Atezolizumab；Carboplatin；Etoposide · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0204 · 北京
- Local Institution - 0336 · 北京
- Local Institution - 0203 · 重庆
- Local Institution - 0308 · 福州
- Local Institution - 0212 · 厦门
- Local Institution - 0234 · 汕头
- Local Institution - 0227 · 哈尔滨
- Local Institution - 0209 · 武汉
- Local Institution - 0208 · 武汉
- Local Institution - 0216 · 长沙
- Local Institution - 0233 · 南昌
- Local Institution - 0244 · 长春
- Local Institution - 0235 · 沈阳
- Local Institution - 0335 · 西安
- Local Institution - 0200 · 济南
- Local Institution - 0206 · 上海
- Local Institution - 0210 · 上海
- Local Institution - 0186 · 上海
- Local Institution - 0330 · 成都
- Local Institution - 0213 · 天津
- Local Institution - 0236 · 杭州
- Local Institution - 0237 · 杭州
- Local Institution - 0229 · 临海
公开的入选条件
- * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
- * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system
- Exclusion Criteria
- * Participants have already received certain types of treatment for extensive stage small cell lung cancer
- * Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sens
- * Other protocol-defined Inclusion/Exclusion criteria apply.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06646276；登记信息更新于 2026-09-11。